La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Sinopharm Group Bilan de santé
Santé financière contrôle des critères 6/6
Sinopharm Group possède un total de capitaux propres de CN¥122.9B et une dette totale de CN¥77.3B, ce qui porte son ratio d'endettement à 62.9%. Son actif total et son passif total sont CN¥413.1B et de CN¥290.2B. L'EBIT de Sinopharm Group est CN¥21.7B ce qui fait que son ratio de couverture des intérêts 10.5. Elle dispose de liquidités et de placements à court terme de CN¥48.9B.
Informations clés
1.3%
Ratio d'endettement
CN¥239.71m
Dette
| Ratio de couverture des intérêts | 10.5x |
| Argent liquide | CN¥8.62b |
| Fonds propres | CN¥17.94b |
| Total du passif | CN¥15.61b |
| Total des actifs | CN¥33.55b |
Mises à jour récentes de la santé financière
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23
Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Recent updates
Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05You Have To Love Sinopharm Group Co., Ltd.'s (HKG:1099) Dividend
Feb 18
Should You Be Impressed By Sinopharm Group's (HKG:1099) Returns on Capital?
Feb 03Should You Use Sinopharm Group's (HKG:1099) Statutory Earnings To Analyse It?
Jan 19At HK$19.00, Is It Time To Put Sinopharm Group Co., Ltd. (HKG:1099) On Your Watch List?
Jan 06What Type Of Shareholders Make Up Sinopharm Group Co., Ltd.'s (HKG:1099) Share Registry?
Dec 25Analyse de la situation financière
Passif à court terme: Les actifs à court terme de 1099 ( CN¥364.5B ) dépassent ses passifs à court terme ( CN¥268.0B ).
Passif à long terme: Les actifs à court terme de 1099 ( CN¥364.5B ) dépassent ses passifs à long terme ( CN¥22.2B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 1099 dispose de plus de liquidités que de sa dette totale.
Réduire la dette: Le ratio d'endettement de 1099 a été réduit de 97.2% à 1.3% au cours des 5 dernières années.
Couverture de la dette: La dette de 1099 est bien couverte par le flux de trésorerie opérationnel ( 6788.6% ).
Couverture des intérêts: Les paiements d'intérêts de 1099 sur sa dette sont bien couverts par l'EBIT ( 10.5 x couverture).